Monte Rosa Therapeutics Overview
- Year Founded
-
2018
- Status
-
Public
- Employees
-
103
- Stock Symbol
-
GLUE
- Share Price
-
$5.79
- (As of Friday Closing)
Monte Rosa Therapeutics General Information
Description
Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their most advanced product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.
Contact Information
Website
www.monterosatx.comCorporate Office
- 321 Harrison Avenue
- Boston, MA 02118
- United States
Corporate Office
- 321 Harrison Avenue
- Boston, MA 02118
- United States
Monte Rosa Therapeutics Stock Performance
As of 21-Mar-2025, Monte Rosa Therapeutics’s stock price is $5.79. Its current market cap is $357M with 61.5M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $5.79 | $7.06 | $3.21 - $12.40 | $357M | 61.5M | 777K | -$0.98 |
Monte Rosa Therapeutics Financials Summary
As of 31-Dec-2024, Monte Rosa Therapeutics has a trailing 12-month revenue of $75.6M.
|
In Thousands, USD |
TTM 31-Dec-2024 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 |
|---|---|---|---|---|
| EV | 227,883 | 227,883 | 150,879 | 141,826 |
| Revenue | 75,622 | 75,622 | 0 | 0 |
| EBITDA | (70,496) | (70,496) | (135,648) | (105,265) |
| Net Income | (72,700) | (72,700) | (135,352) | (108,501) |
| Total Assets | 438,732 | 438,732 | 303,755 | 342,389 |
| Total Debt | 42,715 | 42,715 | 46,039 | 47,001 |
Monte Rosa Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Monte Rosa Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Monte Rosa Therapeutics Comparisons
Industry
Financing
Details
Monte Rosa Therapeutics Competitors (52)
One of Monte Rosa Therapeutics’s 52 competitors is BioTheryx, a Venture Capital-Backed company based in San Diego, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| BioTheryx | Venture Capital-Backed | San Diego, CA | ||||
| Sitryx | Venture Capital-Backed | Oxford, United Kingdom | ||||
| InterAx | Venture Capital-Backed | Villigen, Switzerland | ||||
| Progenra | Formerly VC-backed | Malvern, PA | ||||
| Pyxis Oncology | Formerly VC-backed | Boston, MA |
Monte Rosa Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Monte Rosa Therapeutics Patents
Monte Rosa Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20240285604-A1 | Targeted degradation of vav1 | Pending | 09-Jan-2023 | ||
| US-11912682-B2 | Isoindolinone compounds | Active | 18-Nov-2021 | ||
| US-20230348418-A1 | Isoindolinone compounds | Active | 18-Nov-2021 | ||
| US-20240083869-A1 | Isoindolinone compounds | Pending | 18-Nov-2021 | ||
| US-20250037790-A1 | Degron and neosubstrate identification | Pending | 17-Nov-2021 | G16B15/20 |
Monte Rosa Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Monte Rosa Therapeutics ESG
Risk Overview
Risk Rating
Updated July, 26, 2023
29.34 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,946
Rank
Percentile
Pharmaceuticals
Industry
of 847
Rank
Percentile
Biotechnology
Subindustry
of 366
Rank
Percentile
Monte Rosa Therapeutics FAQs
-
When was Monte Rosa Therapeutics founded?
Monte Rosa Therapeutics was founded in 2018.
-
Where is Monte Rosa Therapeutics headquartered?
Monte Rosa Therapeutics is headquartered in Boston, MA.
-
What is the size of Monte Rosa Therapeutics?
Monte Rosa Therapeutics has 103 total employees.
-
What industry is Monte Rosa Therapeutics in?
Monte Rosa Therapeutics’s primary industry is Drug Discovery.
-
Is Monte Rosa Therapeutics a private or public company?
Monte Rosa Therapeutics is a Public company.
-
What is Monte Rosa Therapeutics’s stock symbol?
The ticker symbol for Monte Rosa Therapeutics is GLUE.
-
What is the current stock price of Monte Rosa Therapeutics?
As of 21-Mar-2025 the stock price of Monte Rosa Therapeutics is $5.79.
-
What is the current market cap of Monte Rosa Therapeutics?
The current market capitalization of Monte Rosa Therapeutics is $357M.
-
What is Monte Rosa Therapeutics’s current revenue?
The trailing twelve month revenue for Monte Rosa Therapeutics is $75.6M.
-
Who are Monte Rosa Therapeutics’s competitors?
BioTheryx, Sitryx, InterAx, Progenra, and Pyxis Oncology are some of the 52 competitors of Monte Rosa Therapeutics.
-
What is Monte Rosa Therapeutics’s annual earnings per share (EPS)?
Monte Rosa Therapeutics’s EPS for 12 months was -$0.98.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
